Illumina, Inc. (ILMN) Director Sells $462,848.85 in Stock
Illumina, Inc. (NASDAQ:ILMN) Director Frances Arnold sold 1,503 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $307.95, for a total value of $462,848.85. Following the completion of the transaction, the director now owns 10,159 shares in the company, valued at approximately $3,128,464.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of NASDAQ:ILMN traded up $2.02 during trading on Wednesday, hitting $306.58. 888,852 shares of the company traded hands, compared to its average volume of 988,017. The firm has a market capitalization of $44.23 billion, a PE ratio of 53.60, a price-to-earnings-growth ratio of 2.09 and a beta of 1.15. Illumina, Inc. has a one year low of $261.61 and a one year high of $372.61. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27.
Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.34 by $0.26. The company had revenue of $846.00 million during the quarter, compared to analyst estimates of $838.70 million. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The business’s revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.45 earnings per share. As a group, analysts predict that Illumina, Inc. will post 6.68 EPS for the current fiscal year.
Several analysts recently weighed in on ILMN shares. BidaskClub lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Canaccord Genuity reissued a “buy” rating and issued a $350.00 price objective (down from $360.00) on shares of Illumina in a report on Friday, April 26th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $355.00 price objective for the company in a report on Tuesday, April 2nd. OTR Global lowered Illumina to a “positive” rating in a report on Tuesday, April 2nd. Finally, Bank of America reissued a “buy” rating and issued a $355.00 price objective on shares of Illumina in a report on Wednesday, January 30th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $353.58.
COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) Director Sells $462,848.85 in Stock” was first reported by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.mareainformativa.com/news/2019/05/15/illumina-inc-ilmn-director-sells-462848-85-in-stock.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Read More: Why do company’s buyback their stock?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.